Explore

Trendline Trendline
Novo Nordisk's IL-6 Inhibitor Ziltivekimab Fails in Cardiovascular Phase 3 Trial, Shares Drop

Novo Nordisk's IL-6 Inhibitor Ziltivekimab Fails in Cardiovascular Phase 3 Trial, Shares Drop

Novo Nordisk's IL-6 Inhibitor Ziltivekimab Fails in Cardiovascular Phase 3 Trial, Shares Drop
Trendline Trendline
Novo Nordisk Faces Setback as Heart Drug Trial Fails to Meet Key Endpoint

Novo Nordisk Faces Setback as Heart Drug Trial Fails to Meet Key Endpoint

Novo Nordisk Faces Setback as Heart Drug Trial Fails to Meet Key Endpoint
Trendline Trendline
Novo Nordisk Faces $30 Billion Market Value Loss After Heart Drug Trial Failure

Novo Nordisk Faces $30 Billion Market Value Loss After Heart Drug Trial Failure

Novo Nordisk Faces $30 Billion Market Value Loss After Heart Drug Trial Failure
Trendline Trendline
Novo Nordisk Shares Drop After Heart Drug Trial Fails to Show Benefits

Novo Nordisk Shares Drop After Heart Drug Trial Fails to Show Benefits

Novo Nordisk Shares Drop After Heart Drug Trial Fails to Show Benefits
Trendline Trendline
Novo Nordisk Faces Setback as Heart Drug Trial Fails, Impacting Stock Value

Novo Nordisk Faces Setback as Heart Drug Trial Fails, Impacting Stock Value

Novo Nordisk Faces Setback as Heart Drug Trial Fails, Impacting Stock Value
Trendline Trendline
Novo Nordisk's Ziltivekimab Heart Drug Fails in Phase 3 Trial, Impacting Stock

Novo Nordisk's Ziltivekimab Heart Drug Fails in Phase 3 Trial, Impacting Stock

Novo Nordisk's Ziltivekimab Heart Drug Fails in Phase 3 Trial, Impacting Stock
Trendline Trendline
Novo Nordisk Shares Plummet After Heart Drug Trial Fails

Novo Nordisk Shares Plummet After Heart Drug Trial Fails

Novo Nordisk Shares Plummet After Heart Drug Trial Fails
Trendline Trendline
Novo Nordisk's ZEUS Trial Fails to Show Cardiovascular Benefits

Novo Nordisk's ZEUS Trial Fails to Show Cardiovascular Benefits

Novo Nordisk's ZEUS Trial Fails to Show Cardiovascular Benefits
Trendline Trendline
Eli Lilly's Stock Surge Driven by New Weight-Management Pill and Strong Financial Performance

Eli Lilly's Stock Surge Driven by New Weight-Management Pill and Strong Financial Performance

Eli Lilly's Stock Surge Driven by New Weight-Management Pill and Strong Financial Performance
Trendline Trendline
Pfizer and Eli Lilly: Divergent Investment Strategies in the Pharmaceutical Sector

Pfizer and Eli Lilly: Divergent Investment Strategies in the Pharmaceutical Sector

Pfizer and Eli Lilly: Divergent Investment Strategies in the Pharmaceutical Sector
Trendline Trendline
Karyopharm's Phase 3 Trial in Endometrial Cancer Shows Mixed Results

Karyopharm's Phase 3 Trial in Endometrial Cancer Shows Mixed Results

Karyopharm's Phase 3 Trial in Endometrial Cancer Shows Mixed Results
Trendline Trendline
Amgen's Monthly Weight Loss Drug MariTide Challenges Eli Lilly and Novo Nordisk

Amgen's Monthly Weight Loss Drug MariTide Challenges Eli Lilly and Novo Nordisk

Amgen's Monthly Weight Loss Drug MariTide Challenges Eli Lilly and Novo Nordisk